Home
World Journal of Biology Pharmacy and Health Sciences
ISSN Approved | International, Peer reviewed, Referred, Open access Journal

Main navigation

  • Home
    • Journal Information
    • Abstracting and Indexing
    • Editorial Board Members
    • Reviewer Panel
    • Journal Policies
    • WJBPHS CrossMark Policy
    • Publication Ethics
    • Current Issue
    • Issue in Progress
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Become a Reviewer panel member
    • Join as Editorial Board Member
  • Contact us
  • Downloads

ISSN Approved Journal | | IMPACT FACTOR 8.16 | | eISSN: 2582-5542 | |  Free Crossref DOI 

Fast Publication within 2 days | | Low Article Processing Charges | | Peer Reviewed and Referred Journal

Research and review articles are invited for publication in September 2026 (Volume 27, Issue 3) Submit Paper

A case report of Steven Johnson’s Syndrome (SJS) /Toxic Epidermal Necrolysis(TEN) overlap caused by Nimesulide

Breadcrumb

  • Home
  • A case report of Steven Johnson’s Syndrome (SJS) /Toxic Epidermal Necrolysis(TEN) overlap caused by Nimesulide

Chirag U Nayee and Amita R Kubavat *

Department of Pharmacology, Pandit Dindayal Upadhyay Medical College and Hospital, Rajkot-360051, India.

Research Article
 
World Journal of Biology Pharmacy and Health Sciences, 2024, 18(02), 154–156.
Article DOI: 10.30574/wjbphs.2024.18.2.0125
DOI url: https://doi.org/10.30574/wjbphs.2024.18.2.0125

Received on 19 February 2024; revised on 06 April 2024; accepted on 08 April 2024

Introduction: Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare, acute and life-threatening mucocutaneous diseases that are nearly always drug-related. Incidence of SJS and TEN is 0.05 to 2 persons per million populations per year. In India, Nimesulide is easily available as an over the counter drug (OTC), different cutaneous reactions associated with, Nimesulide including angioedema, maculo-papular rash, severe urticaria, pityriasis rosea and worsening of preexisting psoriasis.
Patient concern (Case summary): A 17 years old female patient complained about fever and she was prescribed with Tab.Nimesulide twice daily by private practitioner. On the 3rd day of intake of oral Nimesulide, patient developed skin lesions over face, trunk, back and all four limbs. This reaction was diagnosed as Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) overlap by Nimesulide based on clinical picture and drug history.
Interventions: Tab. Nimesulide was stopped and patient was admitted in dermatology ward. Patient was treated with Inj.Hydrocortisone sodium succinate 100mg iv twice daily, Inj.Cefotaxime 1gm iv thrice a daily, Inj. Metronidazole 500mg once a day and Liquid Cyclosporine 50mg twice a day for 10days. Other treatments included Inj. Albumin 100ml i.v slowly for 3 days given. Patient recovered and was discharged after 10 days.
Conclusion: We are presenting a case of SJS-TEN overlap caused by Nimesulide, which is commonly used as an over the counter drug (OTC). Our aims to minimize this type of serious ADR by making alert to physicians and other healthcare professionals, we can avoid hospital admissions because of ADR, reduce economic burden of the patients and health related quality of life of the patient can be improved.

SJS; TEN; Nimesulide; Cutaneous reactions.

https://wjbphs.com/sites/default/files/fulltext_pdf/WJBPHS-2024-0125.pdf

Preview Article PDF

Chirag U Nayee and Amita R Kubavat. A case report of Steven Johnson’s Syndrome (SJS) /Toxic Epidermal Necrolysis(TEN) overlap caused by Nimesulide. World Journal of Biology Pharmacy and Health Sciences, 2024, 18(02), 154–156. Article DOI: https://doi.org/10.30574/wjbphs.2024.18.2.0125

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content


Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


Copyright © 2026 World Journal of Biology Pharmacy and Health Sciences (WJBPHS) - All rights reserved

Developed & Designed by VS Infosolution